PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
-0.01
Negative OCF/share while AGEN has 0.50. Joel Greenblatt would question the viability of operations in comparison.
-0.02
Negative FCF/share while AGEN stands at 0.50. Joel Greenblatt would demand structural changes or cost cuts.
-19.26%
Negative ratio while AGEN is 0.00%. Joel Greenblatt would question whether the firm’s OCF is negative or capex is abnormally large.
0.62
Below 0.5x AGEN's 1.67. Michael Burry would expect an eventual correction in reported profits.
No Data
No Data available this quarter, please select a different quarter.